Strategy and Leadership

Home > Strategy and Leadership

Established in 2008, Therapeutic Innovation Australia (TIA) is the lead agent for the National Collaborative Research Infrastructure Strategy (NCRIS) “Therapeutic Innovation Australia” project funded by the Australian Department of Education. ​

TIA supports national research infrastructure across four capabilities : ​

 • Biologics & Vaccines
• Cell & Gene Therapies

• Small Molecule Therapeutics
• RNA Products

Strategic Plan

We have developed a Strategic Plan for the period 2023-2028 that outlines key strategic aims associated with support of a network of Australian translational research infrastructure.


For the Australian research community to have access to world class research infrastructure to enable efficient translation of therapeutics to improve human health.


TIA will enable and accelerate the translation of research discovery along the therapeutic development pipeline by investing in world class research infrastructure facilities so they are coordinated, comprehensive, accessible and responsive to the needs of the Australian translational research community. 

TIA Board

TIA Ltd is a not-for-profit company limited by guarantee, and is governed by applicable legislation. TIA is overseen by an independent, skills-based Board that meets monthly, and a Governance, Audit and Risk Committee chaired by the Company Secretary that meets every two months. The Board members are knowledgable individuals with extensive experience in the public, private and not-for-profit sectors.

Mr Terry Slater AM


Prof Judith Whitworth AC

MBBS, MD, PhD, DSc (Melb),HonDSc (Glasgow), FRACP, FAICD, FTSE, FAHMS (hon), MD (hon), Syd, MD (hon) UNSW, D Lett (hon) CDU, LD (hon) Melb

Mr Rob Anderson

Company Secretary

Prof Ross McKinnon

B Pharm, B Sci (Hons), PhD, FFIP, FGLF, FAHMS, MAICD


TIA’s management consists of a CEO and a Director of Programs, supported by a Scientific Advisor to the Board and a Board Secretary.

Dr Stuart Newman

Chief Executive Officer

Dr MJ Chua

Director of Programs

A/Prof Stella Clark AM
A/Prof Stella Clark AM

Scientific Adviser to the Board

Lesley Bath

Melbourne Office Manager and Board Secretary

Engagement team

TIA provides support to the sector via a scientific engagement team. These experts in their field are tasked with helping to build and maintain the network of TIA capabilities, as well as provide promotion and referral to TIA facilities.

Mr Ben Hughes

Director of Strategic Development, National Biologics Facility

Dr Heather Donaghy

Scientific Engagement Manager, Cell & Gene Therapies

Dr John Parisot

Strategic Partnerships Advisor


TIA Values Diversity and Equity

Life science and biomedical research enjoys a more favourable gender balance and diversity profile than many other sectors, but as roles become more senior this balance markedly shifts to favour men over women and marginalised groups.

As a source of funding for employment of biomedical research support and technical staff, TIA takes seriously its responsibility to contribute to an appropriate gender balance and a culture of inclusion at all levels of seniority across the sector.

TIA’s staff and Board abide by the following principles:

This pledge is made with the endorsement of the Board and Staff of Therapeutic Innovation Australia Ltd

This pledge is adapted from material from the Champions of Change coalition website. TIA has provided staff with guidance on responding to requests to speak at public events to courteously ask questions on the diversity and gender balance of the panel or program.​

Please contact us to discuss this pledge or other issues of equity and diversity relating to biomedical and life sciences research.